Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1999-04-09
2000-12-05
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
560 13, 560312, 562427, 562430, C07C 31195, C07C31714
Patent
active
061567981
ABSTRACT:
A compound of the formula ##STR1## wherein Y and R.sup.1 are defined in the specification, useful in the treatment of arthritis or cancer and other diseases involving selective inhibition of matrix metalloproteinase-13.
REFERENCES:
patent: 5672615 (1997-09-01), MacPherson et al.
Database Caplus on STN, Acc. No. 1998:147308, Blumenkopf et al., `Preparation of arylsulfonylaminohydroxamic acid derivatives as inhibitors of matrix metalloproteinase and production of tumor necrosis factor.` WO 9807697 A1 (abstract), Feb. 26, 1998.
Database Caplus of STN, Acc. No. 1999:468334, McClure et al., `Matrix metalloprotease (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases.` JP 11199512 A2 (abstract), Jul. 27,1999.
Database Caplus on STN, Acc. No. 1999:464012, Doherty, `MMP inhibitors for the treatment of ocular angiogenesis.` EP 930067 A2 (abstract), Jul. 21, 1999.
Database Caplus on STN, Acc. No. 1999:126875, Robinson, `Preparation of aryloxyarylsulfonylaminohydroxamic acid derivatives as inhibitors of matrix metalloproteinase-13.` WO 9907675 A1 (abstract), Feb. 18, 1999.
Database Caplus on STN, Acc. No. 1998:543047, Robinson et al., `Preparation of arylsulfonylaminoalkylhydroxamates as inhibitors fo matrix metalloproteinases or tumor necrosis factor production.` WO 9833768 A1 (abstract), Aug. 6, 1998.
Davis Brian J.
Ginsburg Paul H.
Jacobs Seth H.
Pfizer Inc
Richardson Peter C.
LandOfFree
Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-962231